TROGARZO (ibalizumab-uiyk)
ANTIRETROVIRAL - ANTI-CD4 DOMAIN 2 MONOCLONAL ANTIBODY · HIV INFECTION
THERATECHNOLOGI
Drug class
Antiretroviral - Anti-CD4 Domain 2 Monoclonal Antibody
The antiretroviral anti-CD4 domain 2 monoclonal antibody drug class consists of specialized biologic entry inhibitors primarily represented by ibalizumab. Read more about Antiretroviral - Anti-CD4 Domain 2 Monoclonal Antibody
1 drugs in this class 1 manufacturers
Drugs in Antiretroviral - Anti-CD4 Domain 2 Monoclonal Antibody
Filter & compare in the drug finder →
Opens the drug finder with Antiretroviral - Anti-CD4 Domain 2 Monoclonal Antibody preselected. Add indication or manufacturer filters there.
The antiretroviral anti-CD4 domain 2 monoclonal antibody drug class consists of specialized biologic entry inhibitors primarily represented by ibalizumab.
These recombinant humanized antibodies selectively bind to the second extracellular domain of the host CD4 receptor without disrupting major histocompatibility complex class II-mediated immune signaling.
This targeted binding induces conformational steric hindrance that prevents post-attachment viral interaction with chemokine co-receptors, thereby halting HIV-1 envelope fusion and cellular penetration.
In clinical practice, agents in this category are indicated in combination with other antiretrovirals for the management of heavily treatment-experienced adults living with multidrug-resistant HIV-1 infection who are experiencing virologic failure on their current therapeutic regimen.
-
la.gov
The antiretroviral anti-CD4 domain 2 monoclonal antibody drug class consists of specialized biologic entry inhibitors primarily represented by ibalizumab
-
fda.gov
The antiretroviral anti-CD4 domain 2 monoclonal antibody drug class consists of specialized biologic entry inhibitors primarily represented by ibalizumab These recombinant humanized antibodies selectively bind to the second extracellular domain of the host CD4 receptor without disrupting major histocompatibility complex class II-mediated immune signaling
-
fda.gov
These recombinant humanized antibodies selectively bind to the second extracellular domain of the host CD4 receptor without disrupting major histocompatibility complex class II-mediated immune signaling This targeted binding induces conformational steric hindrance that prevents post-attachment viral interaction with chemokine co-receptors, thereby halting HIV-1 envelope fusion and cellular penetration
-
accp1.org
This targeted binding induces conformational steric hindrance that prevents post-attachment viral interaction with chemokine co-receptors, thereby halting HIV-1 envelope fusion and cellular penetration
-
fda.gov
In clinical practice, agents in this category are indicated in combination with other antiretrovirals for the management of heavily treatment-experienced adults living with multidrug-resistant HIV-1 infection who are experiencing virologic failure on their current therapeutic regimen
-
clinicaltrials.gov
In clinical practice, agents in this category are indicated in combination with other antiretrovirals for the management of heavily treatment-experienced adults living with multidrug-resistant HIV-1 infection who are experiencing virologic failure on their current therapeutic regimen
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.